US equities
|
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
NVDA
$233.95
▲+0.00%
SNDK
$1,719.99
▲+0.00%
SPCX
$158.96
▲+0.00%
AMD
$633.91
▲+0.00%
WDC
$415.29
▲+0.00%
TSLA
$370.59
▲+0.00%
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
NVDA
$233.95
▲+0.00%
SNDK
$1,719.99
▲+0.00%
SPCX
$158.96
▲+0.00%
AMD
$633.91
▲+0.00%
WDC
$415.29
▲+0.00%
TSLA
$370.59
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Lineage Cell Therapeutics, Inc. Common Stock
(NY:
LCTX
)
0.9303
UNCHANGED
Delayed Quote
Updated: 8:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lineage Cell Therapeutics, Inc. Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Lineage Announces Launch of Phase 2a Study by Genentech of RG6501 (OpRegen®) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
November 28, 2022
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Cell Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
November 10, 2022
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Earnings Preview: Lineage Cell Therapeutics
↗
November 09, 2022
Lineage Cell Therapeutics (AMEX:LCTX) is set to give its latest quarterly earnings report on Thursday, 2022-11-10. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
Lineage Cell Therapeutics to Report Third Quarter 2022 Financial Results and Provide Business Update on November 10, 2022
November 03, 2022
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2022
↗
November 02, 2022
Upgrades
Via
Benzinga
Lineage Cell Therapeutics Appoints Jill Howe as Chief Financial Officer
October 31, 2022
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
A Look At Some Of The Companies Innovating In the Cutting-Edge Regenerative Medicine Field
October 14, 2022
Biotechnology companies have broken many medical barriers in the past 40 years, harnessing the technological revolution to bring innovative solutions to medical problems.
Via
TheNewswire.com
A Look At Some Of The Companies Innovating In the Cutting-Edge Regenerative Medicine Field
October 14, 2022
By David Willey, Benzinga
Via
News Direct
121 Stocks That Hit Their 52-Week Low
↗
October 14, 2022
New Equities that Broke Through 52-Week Lows Friday Morning During Friday's morning session, 121 stocks hit new 52-week lows.
Via
Benzinga
A Look At Some Of The Companies Innovating In the Cutting-Edge Regenerative Medicine Field
↗
October 13, 2022
Biotechnology companies have broken many medical barriers in the past 40 years, harnessing the technological revolution to bring innovative solutions to medical problems.
Via
Benzinga
Lineage Announces Notice of Allowance of Two Patents Covering Processes for Manufacturing Allogeneic Oligodendrocyte Progenitor and Retinal Pigmented Epithelium Cells
October 10, 2022
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage to Present at Alliance for Regenerative Medicine 2022 Cell & Gene Meeting on the Mesa
October 04, 2022
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Establishes New R&D Facility in U.S. and Expands Current GMP Manufacturing Facility in Israel
October 03, 2022
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
EXCLUSIVE: Lineage Cell Establishes New R&D Facility In US, Expands Israel-Based Facility
↗
October 03, 2022
Lineage Cell Therapeutics Inc (NYSE: LCTX) has opened a new research and development facility in Carlsbad, California.
Via
Benzinga
The Three Best Anti-Aging Stocks to Buy in September
↗
September 19, 2022
These three anti-aging stocks could see recovery ahead. ATHX, LCTX, and UBX can make great long-term investments
Via
InvestorPlace
Lineage Cell Therapeutics Earnings Perspective: Return On Capital Employed
↗
September 07, 2022
According to data from Benzinga Pro, during Q2, Lineage Cell Therapeutics's (AMEX:LCTX) reported sales totaled $4.55 million. Despite a 4.38% increase in earnings, the company posted a loss of $6.78...
Via
Benzinga
Lineage to Present at H.C. Wainwright & Co. 2nd Annual Virtual Ophthalmology Conference
August 15, 2022
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Recap: Lineage Cell Therapeutics Q2 Earnings
↗
August 11, 2022
Lineage Cell Therapeutics (AMEX:LCTX) reported its Q2 earnings results on Thursday, August 11, 2022 at 04:05 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Lineage Cell Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
August 11, 2022
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Cell Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on August 11, 2022
August 04, 2022
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
The Daily Biotech Pulse: Pfizer Inks Pact With Africa For COVID-19 Pills, Emergent Bio & Ridgeback To Increase Access To Ebola Treatment, ADC Therapeutics & Sobi In European Pact For Lymphoma Drug
↗
July 08, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2022
↗
June 14, 2022
Upgrades
Via
Benzinga
Lineage Broadens Collaboration With Advanced BioMatrix for HyStem® Cell Drug Delivery Technology
June 02, 2022
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Cell Therapeutics: Q1 Earnings Insights
↗
May 12, 2022
Lineage Cell Therapeutics (AMEX:LCTX) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:05 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Lineage Cell Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
May 12, 2022
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
↗
May 12, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Earnings Preview: Lineage Cell Therapeutics
↗
May 11, 2022
Lineage Cell Therapeutics (AMEX:LCTX) is set to give its latest quarterly earnings report on Thursday, 2022-05-12. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
Lineage Cell Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on May 12, 2022
May 05, 2022
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration
May 03, 2022
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
↗
May 02, 2022
Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
